| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/04/2002 | CA2431571A1 Antisense iap nucleic acids and uses thereof |
| 04/04/2002 | CA2425208A1 Rna aptamers and methods for identifying the same |
| 04/04/2002 | CA2424014A1 A novel human g-protein coupled receptor, hgprbmy7, expressed highly in spinal cord |
| 04/04/2002 | CA2423991A1 Pumpcn compositions and uses thereof |
| 04/04/2002 | CA2423966A1 Peptide ligands for prostate specific antigen |
| 04/04/2002 | CA2423954A1 A novel human g-protein coupled receptor, hgprbmy6, expressed highly in small intestine |
| 04/04/2002 | CA2423953A1 Hydrolases |
| 04/04/2002 | CA2423942A1 Human ion-exchanger proteins and polynucleotides encoding the same |
| 04/04/2002 | CA2423805A1 Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin g |
| 04/04/2002 | CA2423797A1 Antibodies to the propeptide of candida albicans and methods of use |
| 04/04/2002 | CA2423704A1 G-protein coupled receptors |
| 04/04/2002 | CA2423701A1 Oxidoreductases |
| 04/04/2002 | CA2423694A1 Transferases |
| 04/04/2002 | CA2423613A1 Transgenic drosophilia melanogaster expressing beta amyloid |
| 04/04/2002 | CA2423492A1 A fibrin/fibrinogen-binding conjugate |
| 04/04/2002 | CA2423424A1 Secreted proteins |
| 04/04/2002 | CA2423413A1 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 04/04/2002 | CA2423313A1 Methods of treating inflammatory and immune reactions and compositions therefor |
| 04/04/2002 | CA2422890A1 Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents |
| 04/04/2002 | CA2422530A1 Human drug metabolizing enzymes |
| 04/04/2002 | CA2421851A1 Tgf-.beta. inhibitors and methods |
| 04/04/2002 | CA2420960A1 Potassium channel interactors and uses therefor |
| 04/04/2002 | CA2420672A1 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 04/04/2002 | CA2420577A1 Peptide-based compounds |
| 04/04/2002 | CA2420475A1 Ige receptor antagonists |
| 04/04/2002 | CA2420045A1 Melanocortin receptor ligands |
| 04/03/2002 | EP1193272A1 Single-chain insulin analogs |
| 04/03/2002 | EP1192951A2 Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound |
| 04/03/2002 | EP1192943A2 Use of growth hormone secretagogues in conjunction with physical exercise |
| 04/03/2002 | EP1192281A2 Use of ras inhibitors for inhibiting muscle atrophy |
| 04/03/2002 | EP1192280A1 Synthetic ligation reassembly in directed evolution |
| 04/03/2002 | EP1192278A1 48 human secreted proteins |
| 04/03/2002 | EP1192277A2 Diagnostics and therapeutics for restenosis |
| 04/03/2002 | EP1192275A2 Prediction of risk of interstitial lung disease |
| 04/03/2002 | EP1192271A1 Antisense modulation of interleukin-5 signal transduction |
| 04/03/2002 | EP1192265A1 Anti-viral vectors |
| 04/03/2002 | EP1192262A2 Chimeric proteins mediating targeted apoptosis |
| 04/03/2002 | EP1192261A1 22025, a novel human cyclic nucleotide phosphodiesterase |
| 04/03/2002 | EP1192259A1 Tankyrase2 materials and methods |
| 04/03/2002 | EP1192258A2 Human poly(adp-ribose) polymerase 2 materials and methods |
| 04/03/2002 | EP1192257A2 Human regulators of intracellular phosphorylation |
| 04/03/2002 | EP1192256A1 Global regulators of bacterial pathogenic genes; bacterial autoinducer inactivation protein, as targets for engineering disease resistance |
| 04/03/2002 | EP1192253A1 Icbp90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer |
| 04/03/2002 | EP1192252A2 Secreted protein zacrp4 |
| 04/03/2002 | EP1192250A2 Human rna metabolism proteins (rmep) |
| 04/03/2002 | EP1192249A1 47 human secreted proteins |
| 04/03/2002 | EP1192248A1 Antisense modulation of ship-2 expression |
| 04/03/2002 | EP1192247A1 Sphingosine kinase enzyme |
| 04/03/2002 | EP1192243A1 Method for enhancing hematopoiesis |
| 04/03/2002 | EP1192242A1 Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria |
| 04/03/2002 | EP1192184A1 Surfactant protein c esters |
| 04/03/2002 | EP1192182A2 Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
| 04/03/2002 | EP1192181A1 Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor |
| 04/03/2002 | EP1192180A1 Product from starfish |
| 04/03/2002 | EP1192179A2 Compound derived from an offset orf of the ice gene |
| 04/03/2002 | EP1192178A2 Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) |
| 04/03/2002 | EP1192177A1 Statine-derived tetrapeptide inhibitors of beta-secretase |
| 04/03/2002 | EP1192176A1 49 human secreted proteins |
| 04/03/2002 | EP1192174A2 Antagonists of bmp and tgf beta signalling pathways |
| 04/03/2002 | EP1192171A1 48 human secreted proteins |
| 04/03/2002 | EP1192142A1 Cyclo-imino depsipeptides and their utilization in controlling endoparasites |
| 04/03/2002 | EP1191999A1 Method of particle formation |
| 04/03/2002 | EP1191975A2 Improvement of t cell mediated immunity |
| 04/03/2002 | EP1191945A1 Methods and compositions for control of bone formation via modulation of leptin activity |
| 04/03/2002 | EP1191943A1 Novel anti-allergic agents |
| 04/03/2002 | EP1191942A2 Treatment of endometriosis with antileukoprotease |
| 04/03/2002 | EP1191941A1 A method for the prophylaxis and/or treatment of medical disorders |
| 04/03/2002 | EP1191940A1 Tumor necrosis factor receptor 5 |
| 04/03/2002 | EP1191939A1 Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone |
| 04/03/2002 | EP1191845A1 Prevention of brain damage in stroke |
| 04/03/2002 | EP1043974B1 Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus |
| 04/03/2002 | EP0934075B1 Micrococcin atibiotic for the prevention and treatment of mastitis |
| 04/03/2002 | EP0927038B1 P1, p4-dithio-p2,p3-monochloromethylene 5', 5'''-diadenosine p1, p4-tetraphosphate as antithrombotic agent |
| 04/03/2002 | EP0894092B1 A cyclic hepta-peptide derivative from colonial ascidians, lissoclinum sp. |
| 04/03/2002 | EP0856051B1 Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof |
| 04/03/2002 | EP0809512B1 Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin |
| 04/03/2002 | EP0787146B1 Compounds and methods for inhibiting beta-protein filament formation and neurotoxicity |
| 04/03/2002 | EP0775199B1 Superoxide dismutase-4 |
| 04/03/2002 | EP0754049B1 Anti-fungal methods and materials |
| 04/03/2002 | EP0748630B1 Ulinastatin-containing suppository |
| 04/03/2002 | EP0739212B1 Use of interleukin-12 to prevent graft versus host disease |
| 04/03/2002 | EP0738158B1 Biological targeting agents |
| 04/03/2002 | EP0736002B1 Compound capable of introducing at least one molecule into a cell |
| 04/03/2002 | EP0726941B1 Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl |
| 04/03/2002 | EP0722489B1 Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations |
| 04/03/2002 | EP0667163B1 Powder for nasal administration of peptidic or proteinaceous drug |
| 04/03/2002 | EP0666868B1 Use of anti-VEGF antibodies for the treatment of cancer |
| 04/03/2002 | EP0605428B1 Hormone-secreting pancreatic cells maintained in long-term culture |
| 04/03/2002 | EP0573491B1 Mineralized collagen |
| 04/03/2002 | CN1343221A Polypeptide variants with altered effector function |
| 04/03/2002 | CN1343220A Method for producing cyclo-(Asp-Dphe-NMeval-Arg-Gly) |
| 04/03/2002 | CN1343219A Substituted phenethylamine derivatives |
| 04/03/2002 | CN1343217A New amidinobenzylamine derivatives and their use as thrombin inhibitors |
| 04/03/2002 | CN1343212A Derivatives of monosaccharides as well adhesion inhibitors |
| 04/03/2002 | CN1343129A Sustained release salts of pharmaceutically active peptides are their production |
| 04/03/2002 | CN1343127A Potentiation of anti-CD38-immunotoxin cytotoxicity |
| 04/03/2002 | CN1343126A Medicament for treating diabetes |
| 04/03/2002 | CN1343125A Immunostimulant bacterial membrane tractions in cancer treatment |
| 04/03/2002 | CN1343124A Bacterial membrane fractions with adjuvant effect |
| 04/03/2002 | CN1342770A Polypeptide-human protein 10.01 containing phe-His aminolyase active site and polynucleotide for coding it |